Access cutting-edge alport syndrome treatment through this clinical trial at a research site in Dallas. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Dallas location
Preparing your pre-screening questions…
Access alport syndrome specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related alport syndrome treatment provided free
Check if you qualify for this alport syndrome clinical trial in Dallas, TX
No-Cost Study Care
Local to Dallas
Convenient for TX residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Alport syndrome (AS) is a rare genetic condition that causes kidney disease, hearing loss, and eye abnormalities that occur due to changes in specific genes (COL4A3, COL4A4, and COL4A5). These genes help in producing an important protein called collagen. People with AS have a high risk of developing chronic kidney disease (CKD), a condition in which there is progressive loss in kidney function over time. The kidneys soon lose their ability to remove waste products from the body properly, resulting in end-stage kidney disease. A common sign of decreasing kidney function is the presence of excess protein in the urine that is not usually found with healthy kidneys. This condition is known as proteinuria. The study drug, BAY 3401016 (a monoclonal antibody), is a type of medicine that blocks a protein called Semaphorin 3A (Sema3A), which is thought to be involved in causing kidney damage in AS. By blocking the action of the Sema3A protein, BAY 3401016 may prevent proteinuria and slow down the loss in kidney function due to AS. The main purpose of this study is to learn more about how well BAY 3401016 works in slowing down the loss in kidney function in adults with a rapidly progressing AS.
Sponsor: Bayer
Yes, this clinical trial (NCT07211685) has an active research site in Dallas, TX that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for alport syndrome treatment options in Dallas, TX, this clinical trial (NCT07211685) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Dallas research site is actively enrolling participants for this clinical trial. You'll receive care from experienced alport syndrome specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all alport syndrome clinical trials near you to find additional studies recruiting in your area.
See all myalgic encephalomyelitis clinical trials recruiting in Dallas — not just this study.
Browse Myalgic Encephalomyelitis Trials in Dallas →